Abstract
This case examines the research commercialisation process of biotech company living cell technologies (LCT). The case outlines the process of pre-clinical and clinical trials undertaken by the company as they moved towards commercialising their pig islet cell treatment for Type 1 diabetes including the R&D and manufacturing capabilities the firm has developed. Also, the case describes the challenges in bringing a sometimes controversial biotech product to market, including regulatory hurdles; rapid changes to legislation; the impact of public opinion; and the difficulties in raising capital, maintaining cash flow and developing a pipeline of opportunities over a long period of commercialisation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
